Skip to main
HUMA
HUMA logo

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc. has demonstrated significant growth in product sales, with approximately 29 units sold in the latest quarter, a notable increase from 4 units in the previous quarter, indicating a strong upward trajectory in demand. The company has achieved 25 vascular access centers' approval for its Symvess product, expanding its presence to around 92 civilian hospitals, which reflects increasing clinician familiarity and confidence in its technology. Furthermore, positive outcomes from preclinical evaluations and expectations for non-dilutive financing opportunities enhance the company's financial stability and growth potential, reinforcing a favorable outlook for Humacyte's stock.

Bears say

Humacyte Inc faces several significant risks that contribute to a negative outlook on its stock, including potential delays in clinical trial enrollments and product development. The company is also exposed to regulatory risks, which could further hinder its ability to bring products to market in a timely manner, leading to slower commercialization than anticipated. Additionally, the need for additional capital may result in dilution for existing shareholders, compounding the financial challenges for the company.

Humacyte (HUMA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Humacyte (HUMA) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.